Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer

Martin J. Connor* (Corresponding Author), Vincent Khoo, Verity Watson, Ahmed Hashim

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


An estimated 9596 men will be diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC) at presentation in the USA in 2020 [1]. The incidence is predicted to increase to 15 097 diagnoses per year by 2025 [2]. Promisingly, the use of upfront systemic agents such as docetaxel, enzalutamide, abiraterone acetate, and apalutamide, in addition to androgen deprivation therapy (ADT), at diagnosis has led to an impressive increase in overall survival (OS)
from 3.6 yr to a median of 4.8 yr
Original languageEnglish
Pages (from-to)558-560
Number of pages3
JournalEuropean Urology
Issue number4
Early online date3 Feb 2021
Publication statusPublished - Apr 2021

Bibliographical note

Acknowledgments: University College London Hospitals (UCLH) Charity
(Grant No. P83624/1348) & Wellcome Trust (Grant No. 204998/Z/16/Z).




Dive into the research topics of 'Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this